News

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.
Shares of vaccine makers fell after US Health and Human Services Secretary Robert F. Kennedy Jr. raised doubts about the ...
Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...
Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...
Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, with the long-time vaccine critic declaring that vaccines for respiratory bugs that target a sole part of ...
Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.
Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...
In today's Morning Rounds newsletter, RFK Jr.'s latest theory about vaccines, how sweeping FDA layoffs could impact drug ...
Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...
The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial ...
US FDA misses deadline for decision on Novavax's COVID-19 vaccine The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's COVID-19 ...